"""
Question: 1101 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. HIV-1 drug resistance sequence data are available on GenBank (accession numbers MK893083–MK893156).

Rationale: The study describes new sequencing of 74 individuals and provides GenBank accession numbers for these sequences, indicating that the paper reports original, previously unpublished data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. HIV-1 drug resistance sequence data are available on GenBank (accession numbers MK893083–MK893156).

Rationale: The paper explicitly states it performed sequencing of plasma viral RNA and deposited the resulting HIV-1 sequences in GenBank.

Answer: Yes
"""

"""
Question: 1103 

Evidence: This was a retrospective analysis of 74 adolescents and young adults failing recommended first-line treatment from a cohort of 726 HIV-infected adolescents and young adults receiving care and treatment at Newlands Clinic Harare, Zimbabwe between October 2015 and December 2016. The amplicons generated were sequenced by Sanger sequencing at Molecular Cloning Laboratories, San Francisco, CA.

Rationale: The methods describe clinical sample collection and direct Sanger sequencing without any description of laboratory passaging of virus, indicating no in vitro passage experiments were conducted.

Answer: No
"""

"""
Question: 1104 

Evidence: HIV DRMs were determined using the Stanford HIV drug resistance database (HIVdb). Total genotypic susceptibility scores were calculated for first-line regimens (GSS1).

Rationale: The study assessed drug resistance genotypically and calculated genotypic susceptibility scores; there is no mention of phenotypic susceptibility testing or in vitro IC measurements.

Answer: No
"""

"""
Question: 2101 

Evidence: HIV-1 drug resistance sequence data are available on GenBank (accession numbers MK893083–MK893156). We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016.

Rationale: The paper provides a specific GenBank accession range for its sequences, confirming that accession numbers are reported.

Answer: Yes
"""

"""
Question: 2102 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. HIV-1 drug resistance sequence data are available on GenBank (accession numbers MK893083–MK893156).

Rationale: The sequences are derived from patient plasma samples (not laboratory strains), and the accession numbers are provided for these clinical isolates.

Answer: Yes
"""

"""
Question: 2103 

Evidence: HIV-1 drug resistance sequence data are available on GenBank (accession numbers MK893083–MK893156). We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016.

Rationale: The paper directly lists the GenBank accession number range corresponding to the reported sequences.

Answer: MK893083–MK893156
"""

"""
Question: 2202 

Evidence: HIV DRMs were detected in 72/74 (97%) participants after EAC and confirmed VF. NRTI DRMs were found in 84% with the most common being M184V (72%), K65R (41%), and thymidine analog mutations (32%).

Rationale: The paper summarizes mutation frequencies at the cohort level and does not present per-sample mutation lists, indicating that individual isolate mutation lists are not provided.

Answer: No
"""

"""
Question: 2301 

Evidence: HIV-1 drug resistance sequence data are available on GenBank (accession numbers MK893083–MK893156). In a clinic in Harare, we documented the patterns of DRMs and evaluated second-line treatment outcomes among HIV-1-infected adolescents and young adults who had failed a first-line ART regimen despite EAC for 12 weeks.

Rationale: Multiple statements specify HIV-1, establishing the species studied.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: The HIV-1 subtypes with the REGA HIV subtyping tool. HIV DRMs were determined using the Stanford HIV drug resistance database (HIVdb).

Rationale: Although the methods note that subtypes were assessed with the REGA tool, the paper does not report the specific subtype results in the Results or elsewhere.

Answer: NA
"""

"""
Question: 2303 

Evidence: Major NRTI, NNRTI, and PI mutation sites/codons were determined using the Stanford HIVdb. Susceptibility to second generation NNRTIs etravirine (ETR) and rilpivirine (RPV) was estimated based on detection of L100I, K101EP, Y181CIV, Y188L, G190EQ, and M230L as major resistance mutations.

Rationale: Mutation analyses focused on NNRTI and NRTI resistance (reverse transcriptase) and PI resistance (protease), indicating that the sequenced regions were the reverse transcriptase and protease genes within pol.

Answer: Protease and reverse transcriptase (pol)
"""

"""
Question: 2304 

Evidence: Major NRTI, NNRTI, and PI mutation sites/codons were determined using the Stanford HIVdb. HIV DRMs were determined using the Stanford HIV drug resistance database (HIVdb).

Rationale: Determination of NNRTI/NRTI/PI mutations implies analysis of the pol gene (protease and reverse transcriptase), meaning the paper reports results of HIV pol sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. Newlands Clinic is a private voluntary organization founded in Harare, Zimbabwe in 2004 with the aim of providing comprehensive ART services.

Rationale: The study location and sampling site are in Harare, Zimbabwe, indicating the geographic origin of the sequences.

Answer: Zimbabwe (Harare)
"""

"""
Question: 2402 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. Among 726 adolescents and young adults (16--24 years) who were receiving first-line ART at the Newlands Clinic between October 2015 and December 2016, 74 (10%) had a confirmed VL >1,000 copies/mL after 12 weeks of EACGI.

Rationale: Both statements specify the sampling period in 2015–2016.

Answer: 2015–2016 (October 2015 to December 2016)
"""

"""
Question: 2502 

Evidence: The amplicons generated were sequenced by Sanger sequencing at Molecular Cloning Laboratories, San Francisco, CA. The extracted RNA samples were reverse transcribed and amplified using the Southern African Treatment Resistance Network (SATuRN) protocol on the PTC-200 Peltier Thermal Cycler.

Rationale: The sequencing method is explicitly stated as Sanger sequencing.

Answer: Yes
"""

"""
Question: 2503 

Evidence: The amplicons generated were sequenced by Sanger sequencing at Molecular Cloning Laboratories, San Francisco, CA. The SATuRN/Life Technologies genotyping method is a fully integrated protocol for surveillance and monitoring of drug resistance.

Rationale: Sanger sequencing (not NGS) was used, and no next-generation sequencing platform is mentioned.

Answer: No
"""

"""
Question: 2504 

Evidence: For HIV-1 drug resistance genotyping, RNA was extracted using the QIAMP Viral RNA kit (Qiagen, Germany), as per manufacturers' instructions. The amplicons generated were sequenced by Sanger sequencing at Molecular Cloning Laboratories, San Francisco, CA.

Rationale: The workflow describes direct RT-PCR amplification followed by Sanger sequencing of amplicons without mention of cloning prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: The amplicons generated were sequenced by Sanger sequencing at Molecular Cloning Laboratories, San Francisco, CA. The extracted RNA samples were reverse transcribed and amplified using the Southern African Treatment Resistance Network (SATuRN) protocol.

Rationale: The study used population Sanger sequencing of RT-PCR amplicons rather than single-genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: The amplicons generated were sequenced by Sanger sequencing at Molecular Cloning Laboratories, San Francisco, CA. RNA was extracted and reverse transcribed and amplified using the SATuRN protocol.

Rationale: No molecular cloning procedures (e.g., plasmid cloning) are described; sequencing was performed directly on PCR amplicons.

Answer: No
"""

"""
Question: 2601 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. For HIV-1 drug resistance genotyping, RNA was extracted using the QIAMP Viral RNA kit (Qiagen, Germany).

Rationale: The sequencing explicitly targeted plasma viral RNA, indicating plasma HIV sequencing was performed.

Answer: Yes
"""

"""
Question: 2602 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. The plasma VL were obtained in real-time for clinical management with the COBAS AmpliPrep/TaqMan48 HIV-1 quantification system.

Rationale: Only plasma-based measurements and sequencing are described; there is no mention of PBMC-derived sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. HIV-1 drug resistance sequence data are available on GenBank (accession numbers MK893083–MK893156).

Rationale: The abstract states 74 sequenced plasma samples, and the accession number range corresponds to 74 entries.

Answer: 74
"""

"""
Question: 2604 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. The methods only describe plasma RNA extraction and sequencing, with no mention of PBMC DNA sequencing.

Rationale: The paper does not report any PBMC-derived sequencing.

Answer: 0
"""

"""
Question: 2605 

Evidence: Genotyping performed after VF (defined as VL >1,000 copies/mL) was recorded, following weekly enhanced adherence counseling group intervention (EACGI) for 12 weeks. We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART.

Rationale: Sequencing was performed on plasma from individuals with virologic failure and high viral loads, indicating active replication.

Answer: Yes
"""

"""
Question: 2606 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART. For HIV-1 drug resistance genotyping, RNA was extracted using the QIAMP Viral RNA kit.

Rationale: Sequencing targeted plasma viral RNA rather than proviral DNA, indicating sequences were not from the proviral DNA reservoir.

Answer: No
"""

"""
Question: 2701 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years). Among 726 adolescents and young adults (16--24 years) who were receiving first-line ART at the Newlands Clinic between October 2015 and December 2016, 74 (10%) had a confirmed VL >1,000 copies/mL after 12 weeks of EACGI.

Rationale: The study population consisted of adolescents and young adults aged 16–24, not infants or children.

Answer: No
"""

"""
Question: 2702 

Evidence: This was a retrospective analysis of 74 adolescents and young adults failing recommended first-line treatment from a cohort of 726 HIV-infected adolescents and young adults receiving care and treatment at Newlands Clinic Harare, Zimbabwe between October 2015 and December 2016. The clinic provides first- and second-line ART as recommended by the Ministry of Health and Child Care ART program.

Rationale: The study was an observational retrospective analysis within routine care, not a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: This was a retrospective analysis of 74 adolescents and young adults failing recommended first-line treatment from a cohort of 726 HIV-infected adolescents and young adults receiving care and treatment at Newlands Clinic Harare, Zimbabwe between October 2015 and December 2016. The clinic provides first- and second-line ART as recommended by the Ministry of Health and Child Care ART program.

Rationale: As the study is not a clinical trial, it follows that not all individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. HIV DRMs were detected in 72/74 (97%) participants after EAC and confirmed VF.

Rationale: The paper states that sequencing was performed on 74 individuals.

Answer: 74
"""

"""
Question: 3102 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. HIV DRMs were detected in 72/74 (97%) participants after EAC and confirmed VF.

Rationale: The abstract indicates that all 74 individuals were sequenced; detection of DRMs in 72/74 reflects results from those sequences.

Answer: Yes
"""

"""
Question: 4101 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART. First-line ART was provided as FDCs of tenofovir disoproxil fumarate/lamivudine (TDF +3TC), abacavir/lamivudine (ABC +3TC), or zidovudine/lamivudine (AZT +3TC) combined with either efavirenz (EFV) or nevirapine (NVP).

Rationale: All sequenced individuals were failing first-line ART, meaning none were ART-naive.

Answer: No
"""

"""
Question: 4102 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART. First-line ART was provided as FDCs of tenofovir disoproxil fumarate/lamivudine (TDF +3TC), abacavir/lamivudine (ABC +3TC), or zidovudine/lamivudine (AZT +3TC) combined with either efavirenz (EFV) or nevirapine (NVP).

Rationale: The cohort was ART-experienced, hence sequences were from individuals with prior ARV exposure.

Answer: Yes
"""

"""
Question: 4103 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART. First-line ART was provided as FDCs ... combined with either efavirenz (EFV) or nevirapine (NVP).

Rationale: Only ART-experienced individuals were sequenced; there were no ART-naive participants.

Answer: No
"""

"""
Question: 4104 

Evidence: We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART. Of the 74 participants failing NNRTI-based first-line ART, 62 (84%) were switched to a bPI-based second-line ART.

Rationale: All 74 were ART-experienced at the time of sequencing; thus, the number of ART-naive individuals sequenced is zero.

Answer: 0
"""

"""
Question: 4105 

Evidence: First-line ART was provided as FDCs of tenofovir disoproxil fumarate/lamivudine (TDF +3TC), abacavir/lamivudine (ABC +3TC), or zidovudine/lamivudine (AZT +3TC) combined with either efavirenz (EFV) or nevirapine (NVP). Second-line treatment was with a PI, either ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted lopinavir (LPV/r) with TDF +3TC or ABC +3TC or AZT +3TC.

Rationale: The paper provides regimen categories and counts but not detailed, per-individual, complete ART histories; hence complete ART history information for all individuals is not provided.

Answer: No
"""

"""
Question: 4201 

Evidence: Genotyping performed after VF (defined as VL >1,000 copies/mL) was recorded, following weekly enhanced adherence counseling group intervention (EACGI) for 12 weeks. HIV DRMs were detected in 72/74 (97%) participants after EAC and confirmed VF.

Rationale: The study focuses on acquired resistance in individuals failing therapy, not on prevalence of transmitted drug resistance among ART-naive individuals.

Answer: No
"""

"""
Question: 4202 

Evidence: This was a retrospective analysis of 74 adolescents and young adults failing recommended first-line treatment. We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART.

Rationale: The study does not include pretreatment (pre-ART) sequencing to assess pretreatment drug resistance.

Answer: No
"""

"""
Question: 4301 

Evidence: First-line ART was provided as FDCs of tenofovir disoproxil fumarate/lamivudine (TDF +3TC), abacavir/lamivudine (ABC +3TC), or zidovudine/lamivudine (AZT +3TC) combined with either efavirenz (EFV) or nevirapine (NVP). Second-line treatment was with a PI, either ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted lopinavir (LPV/r) with TDF +3TC or ABC +3TC or AZT +3TC.

Rationale: These regimens include NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, and PIs
"""

"""
Question: 4302 

Evidence: Second-line treatment was with a PI, either ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted lopinavir (LPV/r). First-line ART was provided ... combined with either efavirenz (EFV) or nevirapine (NVP).

Rationale: The reported regimens do not include integrase inhibitors; DTG is discussed only in general terms, not as received by participants.

Answer: No
"""

"""
Question: 4303 

Evidence: Second-line treatment was with a PI, either ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted lopinavir (LPV/r). Of the 74 participants failing NNRTI-based first-line ART, 62 (84%) were switched to a bPI-based second-line ART.

Rationale: The paper reports individuals who received protease inhibitors as part of second-line therapy.

Answer: Yes
"""

"""
Question: 4304 

Evidence: The 74 participants ... were receiving treatment with single daily dose regimens; TDF +3TC + EFV/NVP 54 (73%) and ABC +3TC + EFV/NVP 3 (4%), or twice daily regimens of AZT +3TC + EFV/NVP 17 (23%). Second-line ART regimens at switch included TDF + 3TC + ATV/r, AZT + 3TC + ATV/r, AZT + 3TC + LPV/r, ABC + 3TC + ATV/r, and ABC + 3TC + LPV/r.

Rationale: Multiple distinct first- and second-line regimens indicate not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: First-line ART was provided ... combined with either efavirenz (EFV) or nevirapine (NVP). Second-line treatment was with a PI, either ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted lopinavir (LPV/r).

Rationale: Since only NNRTIs and PIs are described and no integrase inhibitors were administered, participants were INSTI-naive.

Answer: Yes
"""

"""
Question: 4403 

Evidence: Of the 74 participants failing NNRTI-based first-line ART, 62 (84%) were switched to a bPI-based second-line ART, one (1%) remained on first-line ART and suppressed at ≥48 weeks of follow-up. The remaining 11 (15%) participants left clinical care and were lost to follow-up.

Rationale: Switching to second-line means those 62 individuals received more than one regimen.

Answer: 62
"""

"""
Question: 4404 

Evidence: Of the 74 participants failing NNRTI-based first-line ART, 62 (84%) were switched to a bPI-based second-line ART. Second-line treatment was with a PI, either ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted lopinavir (LPV/r) with TDF +3TC or ABC +3TC or AZT +3TC.

Rationale: Only first- and second-line regimens are described; no third-line therapy is reported.

Answer: 0
"""

"""
Question: 4405 

Evidence: Of the 74 participants failing NNRTI-based first-line ART, 62 (84%) were switched to a bPI-based second-line ART, one (1%) remained on first-line ART and suppressed at ≥48 weeks of follow-up. The remaining 11 (15%) participants left clinical care and were lost to follow-up.

Rationale: Some remained on first-line, some switched to second-line, hence not all received the same number of regimens.

Answer: No
"""

"""
Question: 4406 

Evidence: Of the 74 participants failing NNRTI-based first-line ART, 62 (84%) were switched to a bPI-based second-line ART. One (1%) remained on first-line ART and suppressed at ≥48 weeks of follow-up.

Rationale: Because the majority switched to a second regimen, not all individuals received only one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: Second-line treatment was with a PI, either ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted lopinavir (LPV/r). A substantial change in public health ART in Africa is the roll-out of FDC of tenofovir, lamivudine, and dolutegravir (TLD) recommended by WHO for first- and second-line treatment.

Rationale: The reported regimens do not include dolutegravir; DTG is discussed only as a recommended regimen generally, not used in this cohort.

Answer: 0
"""

"""
Question: 4502 

Evidence: Second-line treatment was with a PI, either ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted lopinavir (LPV/r). Among the 46 who achieved VS ~50~ on second-line ART, all eight (100%) participants on LPV/r achieved VS ~50~ compared to the 38 (70%) who achieved VS ~50~ on ATV/r.

Rationale: Darunavir is not mentioned among the PIs used; only atazanavir/r and lopinavir/r were administered.

Answer: 0
"""

"""
Question: 5101 

Evidence: HIV DRMs were detected in 72/74 (97%) participants after EAC and confirmed VF. NRTI DRMs were found in 84% with the most common being M184V (72%), K65R (41%), and thymidine analog mutations (32%).

Rationale: The paper provides the total number and percentage of individuals with one or more drug resistance mutations.

Answer: 72
"""

"""
Question: 5102 

Evidence: Major NRTI, NNRTI, and PI mutation sites/codons were determined using the Stanford HIVdb. Susceptibility to second generation NNRTIs etravirine (ETR) and rilpivirine (RPV) was estimated based on detection of specific NNRTI mutations.

Rationale: The study did not sequence or analyze integrase; therefore INSTI-resistance mutations were not assessed and cannot be reported.

Answer: NA
"""

"""
Question: 5103 

Evidence: NRTI DRMs were found in 84% with the most common being M184V (72%), K65R (41%), and thymidine analog mutations (32%). The combination of K65R and M184V, associated with ABC, TDF, and 3TC resistance was identified in 28/74 (38%) participants.

Rationale: K65R is a primary tenofovir resistance mutation; with 41% of 74 individuals harboring K65R, approximately 30 participants had TDF-associated resistance mutations.

Answer: Approximately 30 (41% of 74)
"""

"""
Question: 5104 

Evidence: Major NRTI, NNRTI, and PI mutation sites/codons were determined using the Stanford HIVdb. The SATuRN protocol was designed to be an affordable protocol implementing mostly open source and open access bioinformatics resources for the interpretation of HIV drug resistance.

Rationale: Integrase was not sequenced or analyzed; therefore no INSTI-resistance mutations were reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: Total genotypic susceptibility scores were calculated for first-line regimens (GSS1). Total genotypic susceptibility scores were also calculated for second-line regimens (GSS2).

Rationale: The study used genotypic methods and susceptibility scoring rather than phenotypic susceptibility testing; no phenotypic assay method is described.

Answer: NA
"""

"""
Question: 6102 

Evidence: HIV DRMs were determined using the Stanford HIV drug resistance database (HIVdb). Total genotypic susceptibility scores were calculated for first-line and second-line regimens.

Rationale: There is no report of IC50 or IC90 measurements in the paper.

Answer: No
"""

"""
Question: 6103 

Evidence: Total genotypic susceptibility scores were calculated for first-line regimens (GSS1). Total genotypic susceptibility scores were also calculated for second-line regimens (GSS2).

Rationale: The paper does not report IC50 fold-change data, relying instead on genotypic susceptibility scoring.

Answer: No
"""

"""
Question: 6104 

Evidence: HIV DRMs were determined using the Stanford HIV drug resistance database (HIVdb). Total genotypic susceptibility scores were calculated based on the number of 'active' drugs prescribed using the Rega Institute HIV algorithm on the Stanford HIVdb.

Rationale: No phenotypic susceptibility assay is described; the methods are purely genotypic.

Answer: NA
"""

"""
Question: 6105 

Evidence: HIV DRMs were determined using the Stanford HIV drug resistance database (HIVdb). Total genotypic susceptibility scores were calculated for first- and second-line regimens.

Rationale: The paper does not report replication capacity measurements.

Answer: No
"""

"""
Question: 6106 

Evidence: Total genotypic susceptibility scores were calculated for first-line regimens (GSS1). Total genotypic susceptibility scores were also calculated for second-line regimens (GSS2).

Rationale: No phenotypic drug susceptibility testing was performed; therefore, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: This was a retrospective analysis of 74 adolescents and young adults failing recommended first-line treatment from a cohort of 726 HIV-infected adolescents and young adults. We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART.

Rationale: The study sequenced clinical samples and did not construct or analyze site-directed mutant viruses.

Answer: No
"""

"""
Question: 7102 

Evidence: This was a retrospective analysis of 74 adolescents and young adults failing recommended first-line treatment. The amplicons generated were sequenced by Sanger sequencing at Molecular Cloning Laboratories, San Francisco, CA.

Rationale: The paper does not describe any in vitro passaging of virus; it analyzes patient-derived sequences.

Answer: No
"""